V1RH4 Inhibitors
V1RH4 inhibitors constitute a distinctive class of chemical compounds designed to target and interfere with the V1RH4 protein, an integral component of the V-ATPase complex. The V-ATPase, or vacuolar-type H+-ATPase, is a crucial enzyme complex responsible for pumping protons across cellular membranes, which is essential for maintaining the acidic environment of various intracellular compartments, such as lysosomes, endosomes, and vacuoles. The V1RH4 protein specifically is part of the V1 domain of this complex, contributing to its structural stability and functional capability. The V1RH4 protein interacts with other components of the V1 domain to facilitate the enzyme's activity, which includes ATP hydrolysis and subsequent proton transport.
Inhibitors targeting V1RH4 function by binding to this protein and disrupting its interaction with other components of the V-ATPase complex. This disruption impairs the V1RH4 protein's ability to maintain the structural integrity and operational efficacy of the V-ATPase. Consequently, the proton pump's ability to acidify intracellular compartments is compromised. By obstructing the role of V1RH4, these inhibitors impact the overall function of the V-ATPase complex, leading to potential alterations in the regulation of intracellular pH and related cellular processes. Studying V1RH4 inhibitors provides valuable insights into the specific role of the V1RH4 protein within the V-ATPase complex and enhances understanding of the broader mechanisms governing proton transport and intracellular acidification.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to intracellular calcium depletion, which may downregulate V1R199 expression. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
Cyclopiazonic acid inhibits SERCA, leading to intracellular calcium depletion, which may downregulate V1R199 expression. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil inhibits L-type calcium channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R199 expression. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine inhibits L-type calcium channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R199 expression. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $188.00 $250.00 | 13 | |
Ruthenium Red is a calcium channel blocker that inhibits calcium influx, potentially interfering with the calcium-dependent signaling pathways involved in V1R199 expression. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $103.00 $158.00 $397.00 $656.00 | 2 | |
SKF-96365 inhibits store-operated calcium entry (SOCE), potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R199 expression. | ||||||
Gadolinium(III) chloride | 10138-52-0 | sc-224004 sc-224004A | 5 g 25 g | $153.00 $357.00 | 4 | |
Gadolinium chloride inhibits non-selective cation channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R199 expression. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Dantrolene inhibits calcium release from the sarcoplasmic reticulum, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R199 expression. | ||||||
EGTA | 67-42-5 | sc-3593 sc-3593A sc-3593B sc-3593C sc-3593D | 1 g 10 g 100 g 250 g 1 kg | $21.00 $65.00 $120.00 $251.00 $815.00 | 23 | |
EGTA is a calcium chelator that reduces intracellular calcium levels, potentially inhibiting the calcium-dependent signaling pathways involved in V1R199 expression. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a calcium chelator that reduces intracellular calcium levels, potentially inhibiting the calcium-dependent signaling pathways involved in V1R199 expression. | ||||||